ATG9A loss confers resistance to trastuzumab via c-Cbl mediated Her2 degradation

Acquired or de novo resistance to trastuzumab remains a barrier to patient survival and mechanisms underlying this still remain unclear. Using stable isotope labelling by amino acids in cell culture (SILAC)-based quantitative proteomics to compare proteome profiles between trastuzumab sensitive/resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Nunes, Joao, Zhang, Hua, Angelopoulos, Nicos, Chhetri, Jyoti, Osipo, Clodia, Grothey, Arnhild, Stebbing, Justin, Giamas, Georgios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053674/
https://www.ncbi.nlm.nih.gov/pubmed/27050377
http://dx.doi.org/10.18632/oncotarget.8504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053674/
https://www.ncbi.nlm.nih.gov/pubmed/27050377
http://dx.doi.org/10.18632/oncotarget.8504

Ejemplares similares